The drug tamoxifen is widely used to treat certain breast tumors and to prevent their recurrence. However, half of all recurrences in breast cancer patients are resistant to the drug and often more aggressive tumors result. Now two new studies suggest tests to predict who will benefit from tamoxifen and also explain why the drug so often fails.
